Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE-6 Poor Responders: Pluvicto in mHSPC
NCT06496581Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Sep 2024
- Primary completion
- Feb 2033
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Standard of Care with 177Lu-PSMA-617 + SoC (2 arms). Primary endpoints: Overall Survival at 8.5 years and Radiographic Progression-Free Survival at 8.5 years. Started Sep 2024; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06496581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496581.